Jefferies Assumes Taysha Gene Therapies at Buy, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Eun Yang assumes coverage of Taysha Gene Therapies (TSHA) with a Buy rating and raises the price target to $8.

May 14, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Eun Yang has initiated coverage on Taysha Gene Therapies with a Buy rating and increased the price target to $8, indicating a positive outlook on the company's future.
Analyst ratings and price target adjustments are significant indicators for investors, often leading to short-term price movements. A Buy rating combined with a raised price target suggests strong confidence in the company's prospects, likely resulting in positive investor sentiment and potential upward movement in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100